STOCK TITAN
  1. Home
  2. News
  3. MDXG

Mimedx Group Inc - MDXG STOCK NEWS

Welcome to our dedicated news page for Mimedx Group (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mimedx Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mimedx Group's position in the market.

News
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) will release its first-quarter 2024 operating and financial results on April 30, 2024. The senior management team will host a webcast and conference call to discuss the results. Investors can access the conference call using the provided information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences earnings
-
News
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Rhea-AI Summary
MIMEDX receives a determination letter from the FDA stating AXIOFILL does not qualify as an HCT/P under Section 361, plans to pursue legal options to keep the product on the market. The company reiterates expectations for 2024 net sales growth and adjusted EBITDA margin. Despite the FDA's decision, MIMEDX intends to continue marketing AXIOFILL and has filed a lawsuit in response to the determination letter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
News
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Rhea-AI Summary
MIMEDX Group, Inc. (Nasdaq: MDXG) has entered into an exclusive agreement with TELA Bio, Inc. to commercialize a 510(k) cleared, bovine-derived collagen matrix product for exudating wounds. This partnership aims to enhance MIMEDX's wound care and surgical solutions portfolio, marking a significant step in their growth strategy. The agreement includes immediate addition of the collagen matrix product to MIMEDX's offerings, with plans to introduce more products in the future. Financially, MIMEDX will make an initial $5.0 million payment and potential future payments tied to product sales, ranging from $3.0 million to $7.0 million over the next two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
News
MIMEDX Introduces E-Commerce and Account Management Platform
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) launches MIMEDX Connect™, an online platform to streamline ordering, payment processing, and reimbursement submissions. The platform aims to simplify customer experience by reducing administrative burden and providing a centralized hub for account information. Over 300 customer locations have already started using the platform, reporting time-saving benefits and workflow simplification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
News
MIMEDX Announces Appointment of Two New Independent Directors
Rhea-AI Summary
MiMedx Group, Inc. appoints Tiffany Olson and Dorothy Puhy to its Board of Directors, expanding the board to eleven members. The new directors bring extensive healthcare industry experience and a history of creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
management
-
News
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) reported a 17% year-over-year increase in net sales for the fourth quarter and a 20% increase for the full year 2023. The company achieved a GAAP net income of $53 million for the fourth quarter and $58 million for the full year. Adjusted EBITDA for the fourth quarter was $21 million, representing 24% of net sales. The company launched EPIEFFECT® and converted outstanding Series B convertible preferred stock to common stock. MiMedx expects low double-digit net sales growth in 2024 with an Adjusted EBITDA margin above 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
earnings
News
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) announces participation in TD Cowen 44th Annual Health Care Conference. Senior management to present on March 4, 2024, at 2:10 PM ET. Webcast available for institutional investors. Replay to follow on Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
-
News
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) will release its Q4 and full-year 2023 financial results on February 28, 2024. The webcast and conference call will be hosted by senior management at 4:30 p.m. ET on the same day. Investors can access the call using the provided details. A webcast replay will be available on the company's website for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
conferences earnings
-
News
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
Rhea-AI Summary
MiMedx Group, Inc. (Nasdaq: MDXG) announced the refinancing of its existing indebtedness and obtaining additional borrowing capacity through new senior secured credit facilities totaling $95 million. The Facilities, due in January 2029, consist of a $75 million revolving credit facility and a $20 million term loan facility. The Company drew $50 million under the Facilities, using the proceeds to pay off all outstanding obligations under its existing credit facility with Hayfin Capital. The new debt facility provides greater flexibility, a reduction in interest expense, and additional borrowing capacity to fund organic and inorganic initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
News
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
Rhea-AI Summary
MiMedx Group, Inc. (Nasdaq: MDXG) received a FDA Warning Letter for AXIOFILL classification, not related to safety. The company submitted a Request for Designation for AXIOFILL to the FDA, expecting 2023 net sales growth in the high teens and fourth quarter adjusted EBITDA margin above 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock MDXG logo
Mimedx Group Inc

Nasdaq:MDXG

MDXG Rankings

#2464 Ranked by Market Cap
#123 Ranked by Stock Gains
N/A Ranked by Dividends

MDXG Stock Data

946.41M
116.20M
3.76%
61.47%
3.52%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States
Marietta

About MDXG

mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.